The Smith-Magenis Syndrome Drug market was valued at USD 120.00 Million in 2024 and is expected to reach USD 192.71 Million by 2032, growing at a CAGR of 6.1% (2025-2032). Get insights on trends, segmentation, and key players with Data Bridge Market Research Reports.